United States v. Svete

556 F.3d 1157, 2009 WL 225254
CourtCourt of Appeals for the Eleventh Circuit
DecidedMarch 26, 2008
Docket05-13809
StatusPublished

This text of 556 F.3d 1157 (United States v. Svete) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Svete, 556 F.3d 1157, 2009 WL 225254 (11th Cir. 2008).

Opinion

521 F.3d 1302 (2008)

UNITED STATES of America, Plaintiff-Appellee,
v.
David W. SVETE, Ron Girardot, Defendants-Appellants.

No. 05-13809.

United States Court of Appeals, Eleventh Circuit.

March 26, 2008.

*1303 *1304 Peter Goldberger, Ardmore, PA, E. Brian Lang (Court-Appointed), E. Brian Lang & Associates, Pensacola, FL, Michael S. Pasano, Zuckerman, Spaeder, Taylor & Evans, Miami, FL, for Defendants-Appellants.

Benjamin W. Beard, Pensacola, FL, E. Bryan Wilson, U.S. Atty., Tallahassee, FL, for U.S.

Before DUBINA and KRAVITCH, Circuit Judges, and COOGLER,[*] District Judge.

COOGLER, District Judge:

After a six week jury trial, David W. Svete and Ron Girardot were convicted of conspiracy, mail fraud, money laundering, and interstate transportation of money obtained by fraud, all charges being related to their dealings with viaticals. They now appeal their convictions and present five issues for review. Perhaps the most significant issue is whether the current Eleventh Circuit pattern jury instruction for mail fraud, which omits the requirement of ordinary prudence by investors, is proper. The defendants also challenge the sufficiency of the evidence presented by the government and Svete alleges violations of Brady v. Maryland, 373 U.S. 83, 83 S.Ct. 1194, 10 L.Ed.2d 215 (1963) and Giglio v. United States, 405 U.S. 150, 92 S.Ct. 763, 31 L.Ed.2d 104 (1972) based on inconsistencies between the trial and sentencing testimony of a government witness. Finally, Svete raises two sentencing issues.

Because the jury instruction seriously impaired the defendants' ability to conduct their defense on the substantive counts of mail fraud, we reverse as to those counts. We affirm as to all other issues raised by the defendants.

I. Background

A. Procedural History

Svete and Girardot were charged in a superseding indictment with conspiracy to violate the laws of the United States in violation of 18 U.S.C. § 371 (Count One); conspiracy to launder money in violation of 18 U.S.C. § 1956(h) (Count Two); mail fraud in violation of 18 U.S.C. § 1341 *1305 (Counts Three through Seven); and substantive violations of interstate transportation of money obtained by fraud in violation of 18 U.S.C. § 2314 (Counts Eight through Ten). The jury convicted Svete and Girardot of all counts. Thereafter, the district court sentenced Girardot to a term of imprisonment of 60 months as to Count One and 63 months as to Counts Two through Ten, to run concurrently with one another. In addition, Girardot was ordered to pay a special monetary assessment of $1,000, restitution in the amount of $100,722,605.34, and to serve a 3 year period of supervised release. Svete was sentenced to a term of imprisonment of 60 months as to Count One and 200 months as to Counts Two through Ten, to run concurrently with one another. Svete was also ordered to pay a special monetary assessment of $1,000, restitution in the amount of $100,722,605.34, a $21,000,000 forfeiture, and to serve a 3 year period of supervised release.

B. Facts[1]

1. Introduction

Viaticals are legitimate insurance products in all states, allowing patients ("viators") to sell the right to receive benefits under their life insurance policies for tax-free cash. The sale of viaticals is usually made to a provider company through a broker. The provider company, in turn, typically through a sales agent, finds independent purchasers to invest in the policies. Each purchaser (also referred to as "investor") buys the right to become a beneficiary of the viator's life insurance policy. Thereby, purchasers receive a high return on their investment if the viator dies within the time projected by the viatical settlement provider. However, investors risk a reduction of their return or a complete loss if the viator does not die within the time projected because the investor must continue to pay the premiums on the policy as they accrue or the policy will lapse.

Svete became involved with viaticals in 1997 when he incorporated LifeTime Capital, Inc. ("LCI") in Nevada as a provider company. He later incorporated Alexander Chase, d/b/a WSI, for the same purpose, as well as multiple additional businesses offering financial, office, marketing, and viatical services.[2] According to trial testimony, Svete's control of these corporations was secreted, thus misleading investors and providing an avenue to launder money taken by fraud.

Svete's right hand man was Ron Girardot. Girardot first became employed with Alexander Chase, Svete's financial advisory company, in 1997 as an operations engineer responsible for processes and procedures. In April 1998, Girardot became the temporary President of LCI. From LCI, Girardot moved to another of Svete's companies, Sovereign Enterprises, as Vice President of Operations. Finally, in November 1999, Girardot moved to Svete's Blue Crest, an investment servicing company, as President. As alleged by the government, Girardot's role was to aid in defrauding investors and to launder the money taken by fraud.

During the course of trial, the government presented evidence that defendants defrauded viatical investors by intentionally misrepresenting: (1) life expectancies of viators; (2) the status of the life insurance contracts; and (3) the risks associated with the purchase of certain viatical contracts. *1306 During the time Svete's companies were buying viaticals and selling investments, not less than $101,811,873.88 was invested by at least 3,125 investors. Of that group, at least 1,351 were investors over the age of 65.

2. Evidence of Fraudulent Misrepresentations

Thirty-five witnesses testified during the course of the trial that their investment failed to mature when anticipated. Those investors had been told or provided marketing materials stating that their investment policies concerned terminally ill patients as determined by independent medical specialists who had access to the viators' complete medical records and doctors. This was inaccurate on many levels. Medical doctors were retained to review patient files and estimate life expectancies. However, complete medical records were not provided to those doctors. Instead, they only reviewed medical and laboratory summaries, and did not consult with the attending physicians. Some medical files were submitted for life expectancy review multiple times in an effort to shop for the life expectancy that matched the funded amount. Other times, viator information was never even presented to independent medical doctors for mortality reports. In those instances, Charme Austin, a medical underwriter for Svete, was instructed to create opinions on life expectancy herself and to forge the signatures of independent physicians on those mortality reports. At all times during this process, sales agents were prohibited from obtaining the actual medical information establishing life expectancies.

Additional evidence of fraud perpetuated on investors came in the form of testimony regarding altered contracts.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Orton
73 F.3d 331 (Eleventh Circuit, 1996)
United States v. Cornillie
92 F.3d 1108 (Eleventh Circuit, 1996)
United States v. Sepulveda
115 F.3d 882 (Eleventh Circuit, 1997)
United States v. High
117 F.3d 464 (Eleventh Circuit, 1997)
United States v. Ross
131 F.3d 970 (Eleventh Circuit, 1997)
United States v. Kersey
130 F.3d 1463 (Eleventh Circuit, 1997)
United States v. Dabbs
134 F.3d 1071 (Eleventh Circuit, 1998)
United States v. Humphrey
164 F.3d 585 (Eleventh Circuit, 1999)
United States v. Chastain
198 F.3d 1338 (Eleventh Circuit, 1999)
United States v. Magluta
198 F.3d 1265 (Eleventh Circuit, 1999)
United States v. Odom
252 F.3d 1289 (Eleventh Circuit, 2001)
Larry Eugene Moon v. Frederick J. Head
285 F.3d 1301 (Eleventh Circuit, 2002)
United States v. Fredinand Woodruff
296 F.3d 1041 (Eleventh Circuit, 2002)
United States v. Henry Affit Lejarde-Rada
319 F.3d 1288 (Eleventh Circuit, 2003)
United States v. Darrell B. Gresham
325 F.3d 1262 (Eleventh Circuit, 2003)
United States v. Kevin Wayne Gray
367 F.3d 1263 (Eleventh Circuit, 2004)
United States v. Rigoberto Carrasco
381 F.3d 1237 (Eleventh Circuit, 2004)
LeCroy v. Secretary, Florida Department of Corrections
421 F.3d 1237 (Eleventh Circuit, 2005)
United States v. Phillip Kelley Bobo
419 F.3d 1264 (Eleventh Circuit, 2005)
Peter Ventura v. Attorney General, State of Florid
419 F.3d 1269 (Eleventh Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
556 F.3d 1157, 2009 WL 225254, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-svete-ca11-2008.